Elsevier

Hepatology Research

Volume 22, Issue 3, March 2002, Pages 231-239
Hepatology Research

Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients

https://doi.org/10.1016/S1386-6346(01)00140-1Get rights and content

Abstract

Background: Treatment of hepatitis C virus (HCV) infection with interferon (IFN) in older patients may not be feasible on account of side effects: we, therefore, attempted combined treatment with amantadine hydrochloride (AH) in order to improve not only the flu-like symptoms associated with IFN but also the anti-viral effect. Methods: Patients over 65 years of age, (n=165), who had failed to eradicate HCV infection after previous treatment with IFN were randomized into three groups and treated for 12 months, group A received AH 100 mg twice per day; group B received IFNα-n3 6 M units every other day for 3 months followed by 3 MU and group C the same dose of IFNα-n3, as in B, and AH 200 mg per day. Results: Group A, 42 patients agreed to undergo treatment (genotype 1b n=39); at the end of treatment 21 patients (50%) had normal ALT and seven (17%) negative polymerase chain reaction (PCR). HCV-RNA was not detectable in seven patients at the sixth month follow-up and in six (14%) after 23±2 months. Group B, 39 patients accepted the treatment (genotype 1b n=31); at the end of treatment, 17 patients (44%) had normal ALT and 13 negative PCR (13%). HCV-RNA was not detectable in nine patients (23%) at the sixth month of follow-up and in eight (21%) after 22±4 months. Group C, 38 patients accepted the treatment (genotype 1b n=32); at the end of treatment, 20 (53%) patients had normal ALT and 15 negative PCR (39%). HCV-RNA was not detectable in 15 patients at the sixth month follow-up and in 11 after 21±4 months (29%). Forty-six patients did not accept the scheme of treatment and 26 of them had a follow-up of 20±3 months. HCV-RNA copies and prevalence of genotype 1b were comparable to the treated groups: HCV-RNA was fluctuating or unchanged during the entire follow-up. Conclusions: AH associated with IFN was able to improve the negativization of HCV-RNA and sustained response to IFN and decreased the malaise associated with IFN; an increase in viral copies was observed under AH in about 40%.

Introduction

The risk of developing chronic liver disease and/or hepatocellular carcinoma [1], [2] represents the rationale for treating hepatitis C virus (HCV) infection, and both α-interferon (α-IFN) and α-IFN plus Ribavirin are well accepted treatments [3], [4], [5]. In older patients with long-standing infection and chronic active liver disease, the need to treat has to be balanced against the risk of side effects from both drugs [4], [5], [6].

Preliminary data indicate a beneficial effect of amantadine hydrochloride (AH) on serum transaminases in chronic hepatitis C probably reducing the rate of reinfection of the liver cells by HCV [7], [8], [9]. The mechanism of action appears to be rather aspecific, the molecule interacts in different ways with the cell membrane reducing both internalization and denudation of the virus [10] and has no effect in vitro on protease, helicase, ATPase, polymerase of HCV and has a non-specific translation inhibition [11]. AH is currently used in the prevention of influenza A2 infection [12] and its use, on a large scale, in the elderly has shown AH to be particularly safe in terms of side effects [13], [14], [15].

The aim of this study was to investigate the effect of AH in combination with α-IFN in patients over 65 years of age in whom a previous cycle of treatment had failed to eradicate HCV and in whom, however, there is a specific indication to treat the infection due to the high risk of hepatocellular carcinoma. A second group of patients received AH alone and a third underwent a second course of α-IFN, one of the approved drugs for retreatment of relapsing and non-responding patients in Italy being α-IFNn3.

Section snippets

Patients and methods

The trial was designed with the intention to eradicate HCV infection and a population size of 165 participants was foreseen in order to compare the three treatment schedules and allow a 15% drop-out in 2 years. The trial was approved by the Council of the Department of Clinical Sciences; the use of AH, marketed in Italy for the treatment of Parkinson's disease and influenza, was approved by the Ethics Committee at the University. Patients over 65 years of age (females n=86; males n=79) were

Group A

After enrollment and randomization, two patients refused treatment since AH was experimental, three because the trial did not include IFN and eight patients because of fear of side effects.

Thus 42 patients aged 68±3 years, (F/M:24/18), were then treated with AH 100 mg twice per day for 12 months. Serum ALT and HCV-RNA throughout the study are summarized in Table 2.

At entrance HCV-RNA was 482±227×103 copies per ml in 41/42 patients, in one, although the qualitative PCR was positive, the count of

Discussion

The end point of the present trial of AH, IFNα-n3 and AH plus IFNα-n3 treatment was the eradication of HCV infection and the parameters to establish the result was the number of HCV-RNA copies as shown by the quantitative PCR reaction and number of patients free of HCV at the end of an adequate follow up. From this point of view, the overall success of treatment was 14.4% of patients eradicated out of the 165 individuals enrolled, the overall response at the end of treatment being approximately

Acknowledgements

Work was supported by grants 0280.05.15.01.36 from MURST (Italy) and RC1/98 from St.I.F. Authors are grateful to F. Anzini who managed all outpatient attendances and to Dr C. Berardo, Dr R. Gerardi and Dr R. MA Marinelli who filled in records of majority of patients and to Marian Shields and to Mosha Patsouri for reviewing manuscript.

References (28)

  • M.Y. Lai et al.

    Long term efficacy of ribavirin plus interferon-α in the treatment of chronic hepatitis C

    Gastroenterology

    (1996)
  • F. Russo et al.

    Leucopenia is a side effect of combination therapy for HCV infection

    Am. J. Gastroenterol.

    (2000)
  • K. Ishak et al.

    Histological grading and staging of Chromic hepatitis

    J. Hepatol.

    (1995)
  • L. Pagliaro et al.

    Natural history of chronic hepatitis C

    Ital. J. Gastroentrol. Hepatol.

    (1999)
  • Santolamazza M, Delle Monache M, Alvino A, et al. Natural course of multiple viral infections observed in a group of...
  • National Institute of Health Consensus Development Conference Panel Statement: Management of Hepatitis C. Hepatology...
  • G.L. Davis et al.

    Interferon-α-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C

    New Engl. J. Med.

    (1998)
  • J.P. Smith

    Treatment of chronic hepatitis C with amantadine

    Dig. Dis. Sci.

    (1997)
  • J.A. Findor et al.

    Amantadine HCl alone or associated with recombinant α-IFN.2a during a short term therapy in chronic HCV infection

    Hepatology

    (1997)
  • M. Bacosi et al.

    Treatment of HCV chronic infection with amantadine and interferon in elderly patients

    Hepatology

    (1998)
  • F.Y. Aoki et al.

    Amantadine kinetics in healthy elderly men: implications for influenza prevention

    Clin. Pharmacol. Ther.

    (1985)
  • R. Jubun et al.

    Amantadine and rimantadine have no direct inhibitory effects against hepatitis C viral protease, helicase, ATPase, polymerase, and internal ribosomal entry site-mediated translation

    J. Infect. Dis.

    (2000)
  • D.R. Guay

    Amantadine and rimantadine prophylaxis of influenza A in nursing homes. A tolerability perspective

    Drugs Aging

    (1994)
  • Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP)....
  • Cited by (0)

    View full text